Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30547081 | 0.97 | KCNN4 (0.49) | ALDH1A1MAPK1KCNN4PIK3CDPIK3R1 | |
| SCHEMBL25771269 | 0.97 | KCNN4 (0.49) | ALDH1A1MAPK1KCNN4PIK3CDPIK3R1 | |
| SCHEMBL31435768 | 0.83 | ALDH1A1 (0.44) | ALDH1A1MAPK1KCNN4PIK3R1PIK3CA | |
| SCHEMBL29547174 | 0.83 | ACHE (0.47) | ALDH1A1MAPK1NPC1NFKB1RAB9A | |
| SCHEMBL358976 | 0.83 | ALDH1A1 (0.67) | ALDH1A1MAPK1TAAR1LMNANPC1 | |
| SCHEMBL197834 | 0.83 | ACHE (0.47) | ALDH1A1MAPK1NPC1NFKB1RAB9A | |
| SCHEMBL31295703 | 0.83 | ALDH1A1 (0.67) | ALDH1A1MAPK1TAAR1LMNANPC1 | |
| SCHEMBL20582873 | 0.80 | ALDH1A1 (0.46) | ALDH1A1MAPK1KCNN4HTTLMNA | |
| Hydrogen Sulfide SCHEMBL10700223 | 0.80 | ACHE (0.45) | ALDH1A1MAPK1NPC1NFKB1RAB9A | |
| SCHEMBL31465796 | 0.80 | ALDH1A1 (0.63) | ALDH1A1MAPK1KCNN4HTTTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035339-A1 | TETRAHYDRONAPHTHALENE DERIVATIVE | ATRANSEN PHARMA LTD (JP) | 2026-02-05 | — | — | US | disclosed |
| US-20250311627-A1 | LIGHT-EMITTING DEVICE INCLUDING HETEROCYCLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND THE HETEROCYCLIC COMPOUND | SAMSUNG DISPLAY CO., LTD. (KR) | 2025-10-02 | — | — | US | disclosed |
| US-20250270195-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-08-28 | — | — | US | disclosed |
| US-12338233-B2 | PD-1/Pd-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| EP-4501906-A1 | TETRAHYDRONAPHTHALENE DERIVATIVE | Atransen Pharma Ltd. (JP) | 2025-02-05 | — | — | EP | disclosed |
| CN-118974007-A | Tetrahydronaphthalene derivatives | 阿创森制药股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118084940-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2024-05-28 | — | — | CN | disclosed |
| WO-2023190878-A1 | TETRAHYDRONAPHTHALENE DERIVATIVE | Ａｔｒａｎｓｅｎ Ｐｈａｒｍａ株式会社 | 2023-10-05 | — | — | WO | disclosed |
| EP-4227302-A1 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| CN-102030653-B | Polymerizable compound | DAINIPPON INK & CHEMICALS CO LTD | 2015-07-01 | — | — | CN | disclosed |
| US-7858624-B2 | Piperidine and morpholine renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090275581-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090264428-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264432-A1 | Piperidine and Morpholine Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090074890-A1 | Substituted Triazoles as Sodium Channel Blockers | MERCK SHARP & DOHME CORP. | 2009-03-19 | — | — | US | disclosed |
| US-7459475-B2 | Substituted triazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2008-12-02 | — | — | US | disclosed |
| EP-1694654-A2 | SUBSTITUTED TRIAZOLES AS SODIUM CHANNEL BLOCKERS | Merck & Co., Inc. (US) | 2006-08-30 | — | — | EP | disclosed |
| US-20060020006-A1 | Substituted triazoles as sodium channel blockers | MERCK SHARP & DOHME LLC | 2006-01-26 | — | — | US | disclosed |
| WO-2005047270-A2 | SUBSTITUTED TRIAZOLES AS SODIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | ALDH1A1 115/4885MAPK1 1362/4885KCNN4 4861/4885 |
| US-20090275581-A1 | RENIN INHIBITORS | REN, ACE, SERPINB1 | ALDH1A1 1084/4885MAPK1 1494/4885KCNN4 3041/4885 |
| US-20090074890-A1 | Substituted Triazoles as Sodium Channel Blockers | TRPV1, SCN3A, SCN5A | ALDH1A1 1306/4885MAPK1 2006/4885KCNN4 80/4885 |
| US-12338233-B2 | PD-1/Pd-L1 inhibitors | PDCD1, CD274, PDCD1LG2 | ALDH1A1 115/4885MAPK1 1362/4885KCNN4 4861/4885 |
| US-20090264432-A1 | Piperidine and Morpholine Renin Inhibitors | REN, ACE, PREP | ALDH1A1 2168/4885MAPK1 1239/4885KCNN4 325/4885 |
| US-20250270195-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | ALDH1A1 115/4885MAPK1 1362/4885KCNN4 4861/4885 |
| US-20260035339-A1 | TETRAHYDRONAPHTHALENE DERIVATIVE | LATS1, LATS2, BCAT1 | ALDH1A1 1267/4885MAPK1 152/4885KCNN4 3185/4885 |
| US-20090264428-A1 | Renin Inhibitors | REN, ACE, SERPINB1 | ALDH1A1 1060/4885MAPK1 2221/4885KCNN4 3141/4885 |
| US-20060020006-A1 | Substituted triazoles as sodium channel blockers | TRPV1, SCN3A, SCN5A | ALDH1A1 1347/4885MAPK1 1936/4885KCNN4 80/4885 |
| US-20250311627-A1 | LIGHT-EMITTING DEVICE INCLUDING HETEROCYCLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND THE HETEROCYCLIC COMPOUND | LAGE3, CRY1, EMC1 | ALDH1A1 16/4885MAPK1 964/4885KCNN4 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.